New Drug Delays Progression of Deadly Brain Cancer
A novel targeted therapy drug, vorasidenib, has been shown to more than double the progression-free survival in patients with a subtype of glioma, according to an international study co-led by UCLA. By inhibiting mutant IDH1/2, the drug delays chemotherapy and radiation by almost 17 months, providing a breakthrough treatment for this deadly brain tumor.Study is the first clinical trial analyzing a targeted therapy specifically developed to treat brain tumors.A targeted therapy drug called vorasidenib had positive results…